The ABIDE-PET study.
Recruiting
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, PET, florbetaben, dementia
- Registration Number
- NL-OMON21592
- Lead Sponsor
- VU Medical Center.
- Brief Summary
n.a.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
All patients presenting at VUmc memory clinic will be invited to participate in the study.
Exclusion Criteria
Patients who
- are mentally incompetent
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main outcome measure is the clinical value of [18F]FBB PET, which will be operationalized as follows. (i), the change in diagnosis, (ii) change in the level of confidence in the diagnosis, (iii) .the impact on future patient management as measured using additional ancillary investigations, prescription of medication and use of health care.
- Secondary Outcome Measures
Name Time Method In addition, patients who do not (yet) have dementia (i.e. subjective complaints, MCI), clinical progression to MCI or dementia during annual follow-up (based on follow-up visits to neurologist and neuropsychologist) will serve as additional outcome measure. Furthermore, in a subset of demented patients we will obtain clinical follow-up to examine the relation with rate of progression.